Skip to main content
Clinical Trials/ITMCTR2100004855
ITMCTR2100004855
Recruiting
Phase 1

A randomized, double-blind, controlled study on the treatment of stable vitiligo with compound Honghuabuji granules

Shanghai Dermatology Hospital0 sitesTBD

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Not specified
Sponsor
Shanghai Dermatology Hospital
Status
Recruiting
Last Updated
3 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
3 years ago
Study Type
Interventional study
Sex
All

Investigators

Sponsor
Shanghai Dermatology Hospital

Eligibility Criteria

Inclusion Criteria

  • 1\. Patients who are clearly diagnosed as vitiligo, and those who have been diagnosed as blood stasis syndrome by Chinese medicine;
  • 2\. Patients aged 18 to 60 years;
  • 3\. Mainly confined and sporadic;
  • 4\. In order to accurately compare the test results, the hypopigmented area of all patients in this test is \<\= 10% of the total body surface area;
  • 5\. No systemic or topical glucocorticoid or immunosuppressant treatment or withdrawal of the drug for more than 3 months within 3 months;
  • 6\. Patients with leukoplakia that have not expanded within 6 months and are in a stable phase;
  • 7\. Patients who agree to take pictures of the skin lesions and can complete the treatment and follow\-up on time.

Exclusion Criteria

  • 1\. Pregnant and lactating women;
  • 2\. System or topical vitiligo drug treatment within 3 months;
  • 3\. Patients who are allergic to tacrolimus ointment and compound Honghuabuji granules.
  • 4\. Patients with severe heart, liver, kidney and other system diseases;
  • 5\. Patients who withdraw halfway and have incomplete information.

Outcomes

Primary Outcomes

Not specified

Similar Trials